Inovio Pharmaceuticals (INO) to Release Quarterly Earnings on Tuesday

Key Points

• Inovio will release Q1 2026 results after market close on Tuesday, May 12, with a conference call on May 13 at 4:30 PM ET; analysts are forecasting ($0.30) EPS and $0.333M revenue.
• Inovio unexpectedly reported $0.31 EPS in its last quarter (Mar 12), topping estimates, but analysts still project roughly -$1 EPS for the current and next fiscal years.
• The stock recently traded around $1.17 with a market cap of about $80.9M; Wall Street consensus is a Hold with a $6.75 average price target (4 Buy, 3 Hold, 1 Sell).

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $0.3330 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.68. On average, analysts expect Inovio Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO traded up $0.03 during trading hours on Tuesday, reaching $1.17. The company's stock had a trading volume of 502,120 shares, compared to its average volume of 1,568,146. The company has a market capitalization of $80.90 million, a P/E ratio of -0.70 and a beta of 1.43. Inovio Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $2.98. The stock has a 50 day moving average price of $1.46 and a two-hundred day moving average price of $1.77.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INO. Oppenheimer reaffirmed an "outperform" rating on shares of Inovio Pharmaceuticals in a research report on Friday, March 13th. Wall Street Zen raised Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $6.75.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Large investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 5,894 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Inovio Pharmaceuticals by 752.9% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 18,160 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Inovio Pharmaceuticals during the third quarter valued at $41,000. Millennium Management LLC grew its holdings in shares of Inovio Pharmaceuticals by 468.7% during the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company's stock valued at $4,616,000 after buying an additional 1,625,653 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Inovio Pharmaceuticals by 855.5% during the third quarter. XTX Topco Ltd now owns 210,567 shares of the biopharmaceutical company's stock valued at $493,000 after buying an additional 188,529 shares during the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.